Wave Life Sciences (NASDAQ: WVE) shares have been cut in half on Thursday, even though the biotechnology company reported Phase 1 data for an obesity drug that management dubbed “positive”.
The sudden pressure drove WVE decisively below its 200-day moving average (MA) – a “bearish” technical setup that often triggers further algorithmic selling.
Year-to-date, WVE stock is now down more than 60%, but Oppenheimer analyst Cheng Li remains undeterred, calling investing in this biotech firm at the current price a generational opportunity.
Why Wave Life Sciences stock crashed despite positive data
Management called the trial results “positive” mostly because the lower 240 mg dose of the WVE-007 injection helped participants shed 14% of the visceral fat while gaining 2% in lean muscle in six months.
However, the disconnect for investors was the higher 400 mg dose that failed to show a “superior” response.
At three months, the 400 mg cohort saw only a 5% decline in visceral fat and “negligible” overall weight loss.
WVE shares tanked on Mar. 26 as this lack of “more is better” efficacy signalled a potential ceiling for the drug’s potency.
In short, in a market dominated by GLP-1 heavyweights that deliver double-digit decline in weight, WVE-007’s modest (less than 1%) loss at higher doses raises fears that it may struggle to compete as a standalone treatment.
Why Oppenheimer still recommends buying WVE shares
Despite the higher dose disappointment, Oppenheimer reiterated its “outperform” rating on Wave Life Sciences stock this morning with a $32 price target, indicating a staggering 5x potential.
According to the investment firm, the 400 mg data was likely skewed by uncertainty around patient baseline characteristics rather than a failure of the drug itself.
Meanwhile, the 240 mg dose actually met its expectations, delivering a 14% reduction in visceral fat at six months.
They dubbed the 400 mg anomaly a statistical outlier caused by cohort variability that will likely be fixed in Phase 2a.
Crucially, WVE-007 maintained a clean safety profile with no treatment discontinuations or severe adverse events reported up to 600 mg – confirming the drug’s tolerability.
Should you buy the dip in WVE stock today?
Beyond the INLIGHT trial, Oppenheimer highlighted WVE’s pipeline and strategic positioning as key value drivers.
The company is advancing programs in MASH, type 2 diabetes, and cardiovascular disease, with Phase 2a trials set to begin in Q2 2026.
Note that Wave Life Sciences shares’ 14-day relative strength index (RSI) does not sit in the late teens, indicating extremely oversold conditions that often trigger a relief rally.
Interestingly, Oppenheimer is actually among the more conservative Wall Street analysts on WVE.
The consensus rating on the biotech firm sits at “strong buy”, with the mean target of $35 signaling massive upside potential as the year unfolds.
https://invezz.com/news/2026/03/26/wave-life-sciences-stock-crash-analyst-explains-why-its-a-buying-opportunity/
